PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-73.61%
G&A reduction while AVXL shows 149.01% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-74.78%
Operating expenses reduction while AVXL shows 48.12% growth. Joel Greenblatt would examine advantage.
-74.78%
Total costs reduction while AVXL shows 48.12% growth. Joel Greenblatt would examine advantage.
5.73%
Interest expense growth while AVXL reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
74.78%
EBITDA growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
74.78%
Operating income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.85%
Tax expense reduction while AVXL shows 0.00% growth. Joel Greenblatt would examine advantage.
64.85%
Net income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
64.71%
EPS growth while AVXL declines. John Neff would investigate advantages.
64.71%
Diluted EPS growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.